Advances in the treatment of metastatic prostate cancer
-
Published:2023-10
Issue:10
Volume:9
Page:840-854
-
ISSN:2405-8033
-
Container-title:Trends in Cancer
-
language:en
-
Short-container-title:Trends in Cancer
Author:
Gebrael GeorgesORCID,
Fortuna Gliceida Galarza,
Sayegh Nicolas,
Swami Umang,
Agarwal Neeraj
Subject
Cancer Research,Oncology
Reference54 articles.
1. Cancer statistics, 2023;Siegel;CA Cancer J. Clin.,2023
2. Advanced prostate cancer: treatment advances and future directions;Swami;Trends Cancer,2020
3. Darolutamide and survival in metastatic, hormone-sensitive prostate cancer;Smith;N. Engl. J. Med.,2022
4. Abiraterone plus prednisone added to androgen deprivation therapy and docetaxel in de novo metastatic castration-sensitive prostate cancer (PEACE-1): a multicentre, open-label, randomised, Phase 3 study with a 2×2 factorial design;Fizazi;Lancet,2022
5. Darolutamide plus androgen-deprivation therapy and docetaxel in metastatic hormone-sensitive prostate cancer by disease volume and risk subgroups in the Phase III ARASENS trial;Hussain;J. Clin. Oncol.,2023
Cited by
16 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献